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Investing in Exposure
Abdul Moiz Khan
The problems of the overwhelming amount of medical 
literature have been thoughtfully highlighted in the PLoS 
Medicine editorial “Drowning or Thirsting: The Extremes 
of Availability of Medical Information” [1]. It is of vital 
importance to medical professionals that they improve on 
their skills of sifting through the huge amounts of literature 
that are made available to them every month. But this task 
becomes exponentially more difﬁ  cult in the less-developed 
world, where basic knowledge of medical literature is 
limited [2]. 
There are no alternatives to the good analytical skills that 
come through continued exposure to medical literature. This 
exposure should begin at the medical student level. Exercises 
such as those requiring medical students to analytically 
criticize medical literature can go a long way in developing 
reading skills.
The second issue is that of disseminating the literature that 
has been published. Access to reliable health information 
has been described as “the single most cost-effective and 
achievable strategy for sustainable improvement in health 
care” [3].
A useful strategy could be making less-expensive paper 
versions of medical journals widely available in less-developed 
countries. Publishers should be willing to look into this 
approach. Regional copies of journals can be produced 
locally and inexpensively. This will boost the circulation of 
medical journals. Medical professionals will not mind a little 
compromise in the quality of paper in a journal, so long as 
they are able to afford it at a low price.
The business model of offshore call centers can serve 
as a useful one in the case of publishing low-cost copies of 
medical journals. Companies have shifted their call centers to 
less-developed countries where services are available at very 
low costs. The costs of publishing are likewise bound to be 
cheaper in the less-developed countries; therefore, journals 
can be produced at affordable prices. If this model can be 
followed by multinationals, why is it not possible for a cause as 
noble as publishing medical literature?
Another approach could be that journal volumes could be 
condensed, so that only research relevant to the local area is 
published in the local version of the journal.
The Internet’s widely spreading use as a resource can 
be of vital value in substantially quenching the thirst of 
professionals. The wide availability of Internet access in 
Pakistan [4], for example, helps the cause of disseminating 
information. Internet access such as that given through the 
platform of HINARI or the Ptolemy project [5] is also a viable 
option. But these networks need to be expanded to include 
more countries and individuals [6].
One should hope that investing in improving exposure of 
health professionals to medical literature will help improve 
their practices and the quality of healthcare that they provide 
to impoverished populations in their local area. The need of 
the hour is to be innovative and be ready to embrace new and 
thoughtful ideas for the collective good of humanity.  
Abdul Moiz Khan (E-mail: amoiz269@hotmail.com)
Jhang, Punjab, Pakistan
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Hyperinfectivity in Cholera: 
A New Mechanism for an Old 
Epidemiological Model?
Mercedes Pascual, Katia Koelle, Andrew P. Dobson
Hartley et al. [1] have recently proposed an epidemiological 
model for the dynamics of cholera that explicitly incorporates 
a hyperinfectious stage of the pathogen Vibrio cholerae, 
following laboratory ﬁ  ndings that passage of the bacterium 
through the gastrointestinal tract results in a short-lived 
more highly infectious state. The paper and its commentary 
[2] emphasize that this model provides a basis for the 
transmission pathway known as “human-to-human” and 
demonstrates its importance, relative to the “environment-
to-human” pathway, in the “explosive” character of cholera 
epidemics. Nevertheless, several important points seem to be 
missing from the discussion. 
First, epidemiological models that treat transmission as 
“human-to-human” do exist in both the older literature [3] 
and in more recent cholera studies [4,5]. The latter use 
time series models to explain the interannual dynamics of 
cholera outbreaks in endemic areas. Their application to the 
temporal patterns of cholera in both recent and historical 
records from Bangladesh show that the force of infection is 
clearly related to previous incidence levels, as expected for 
“human-to-human” transmission. This work has also shown 
that environmental variables (El Niño, rainfall) modulate this 
type of transmission [5], so that the focus on the environment 
is relevant even for the “human-to-human” pathway. 
Second and more importantly, we can ask whether the 
model of Hartley et al. differs from the standard treatment 
of “human-to-human” transmission in epidemiological 
models. In particular, does the so-called “explosive” behavior 
differ from the well-known exponential growth of cases 
at the beginning of an epidemic, when there is little or PLoS Medicine  |  www.plosmedicine.org 0932
no immunity built into the population? Inspection of the 
temporal scales involved in the dynamics tells us that this is 
not the case: we can collapse their treatment of transmission 
via a hyperinfectious stage into a more standard direct-
transmission formulation. This is because the dynamics of 
the hyperinfectious stage in the environment are much faster 
than that of the number of cases, with the average lifespan of 
a hyperinfectious bacterium (their variable BHI) being on the 
order of 5 h, whereas an infected individual (their variable 
I) continues to shed for approximately 5 d. Therefore, to a 
ﬁ  rst approximation, BHI sees I as “constant” for a sufﬁ  cient 
length of time to reach “equilibrium” for any given value 
of I. It follows that this “equilibrium” concentration of the 
hyperinfectious stage in the environment effectively tracks 
the size of the infected population; in other words, BHI 
is simply proportional to I. Simulations of the model with 
the parameter values of the Hartley et al. paper conﬁ  rm 
this expectation for the whole course of an epidemic. We 
can then get rid of this variable and write the transmission 
rate as a function of the number of susceptibles and the 
number of infected individuals, as is traditionally done in 
epidemiological models. Thus, for purposes of modeling 
cholera epidemics, we do not need to explicitly represent the 
hyperinfectious stage, unless the questions and mechanisms 
we are examining are speciﬁ  cally about this stage (as was the 
case in Hartley et al.), and “explosive” behavior does not refer 
to a different type of dynamics than that of standard models 
for human-to-human transmission. 
There is another way, however, in which the epidemics 
may have been called “explosive” by Hartley et al.: the growth 
rate of the epidemics in their model is much higher when 
“human-to-human” transmission becomes dominant relative 
to “environment-to-human” transmission. This brings us 
to the important epidemiological quantity known as R0, 
which measures the number of secondary cases produced 
by an infected individual in a pool of susceptibles, that is, 
at the beginning of an outbreak. Hartley et al. report a 
new formula for cholera’s R0 (Equation 4 in their paper). 
There is an interesting discrepancy between Hartley et al.’s 
R0 estimate when “human-to-human” is dominant (R0, 
~18) and the value we obtain for cholera data for Matlab, 
Bangladesh (R0, ~3) (unpublished result). Our estimate is 
close to the values Hartley et al. propose when “environment-
to-human” transmission is dominant, even though our 
estimate is obtained from a model of “human-to-human” 
transmission. As far as we can tell from the information 
provided, the derived expression for R0 in Hartley et al. is an 
approximation. It appears to hold exactly when the dynamics 
of both the hyperinfectious and the environmental stage 
occur on fast temporal scales, quickly “equilibrating” and 
tracking the number of cases. While this assumption, as we 
have argued, applies to the hyperinfectious stage, it does not 
to the environmental one, as demonstrated by similar model 
simulations. Hartley et al.’s expression for R0 would then 
overestimate the reproductive number of the disease, making 
it more explosive than it is (see Figure 4 in the paper). 
The discrepancy in our estimates has an important 
consequence: while an epidemic declines from a depletion 
of susceptibles in the Hartley et al. model, the seasonal 
outbreaks we observe in Bangladesh are curtailed prior to 
a signiﬁ  cant depletion of susceptibles [5]. This implies that 
the transmission rate must effectively be decreasing as the 
epidemic peaks. Indeed, recent observations of vibriophage 
dynamics in Bangladesh have given rise to the hypothesis that 
seasonal outbreaks may be self-limiting due to ampliﬁ  cation 
of Vibrio-speciﬁ  c phage [6,7]. The dynamics of phage 
predation are a likely mechanism for the observed reduction 
in cholera transmission rate at the end of seasonal outbreak. 
Despite these differences, both our analyses and Hartley 
et al.’s model accentuate the need to consider some variant 
of “human-to-human” transmission to explain cholera 
dynamics. An important issue is therefore what we should call 
“human-to-human” transmission. Clearly, the categorization 
of the two routes of transmission (“human-to-human” and 
“environment-to-human”) is a simpliﬁ  cation, albeit useful for 
the purpose of modeling the disease, that considers only the 
two extremes of a continuous axis deﬁ  ned by the strength of 
the feedback between (previous) cases and transmission rate 
and by the different temporal scales of transmission. For the 
“environment-to-human” type, this feedback is weak (in the 
extreme, nonexistent) as the bacterium concentration in the 
environment becomes dominated by its survival, population 
growth, environmental drivers, and the stochastic nature 
of these processes. At the other extreme, the feedback is 
strong and the transmission rate is a function of cases. This 
deﬁ  nition is more general and more practical than the 
one that restricts “human-to-human” transmission to that 
mediated by the hyperinfectious state. For issues of control, 
the more general deﬁ  nition appears more relevant, unless 
we are considering control measures that would speciﬁ  cally 
target the concentration of the hyperinfectious stage. 
Many open questions remain on the modeling of cholera 
in connection to transmission pathways. For example, 
early-warning systems and associated predictive models for 
endemic and epidemic regions remain to be developed and 
tested. In contrast, the importance of sanitary conditions, 
sewage treatment, and clean water for cholera prevention 
and eradication has been known for a very long time. 
Nevertheless, cholera is today in its seventh pandemic and, as 
a “disease of poverty” [8], continues to represent a signiﬁ  cant 
public health burden around the world. Neither an exclusive 
focus on the environment nor an emphasis on socio-economic 
factors alone is sufﬁ  cient to address the cholera problem 
today. Developing a better mechanistic understanding of 
the factors that initiate, amplify, and defuse regular seasonal 
outbreaks in endemic areas and irregular “epidemic” 
outbreaks in others should prove valuable to develop viable 
control strategies for this and other enteric diseases.  
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Industry and Bioethics: What Price 
the Relationship?
Mark Boyd, Wendy Rogers
We read with interest the article by Mackie et al. entitled 
“Lessons on Ethical Decision Making from the Bioscience 
Industry” [1]. The authors recognise some study limitations, 
including the possibility of social desirability bias, but fail to 
address other limitations that in our view seriously weaken the 
paper. 
Firstly, there is no discussion regarding an understanding 
of the use of the term “ethics” by the authors and bioscience 
companies. There appears to be an assumption that “ethics” 
is a straightforward term whose meaning would be agreed 
by all those engaged in the ﬁ  eld. However, the requirements 
of business ethics, for example, may differ signiﬁ  cantly from 
the requirements of healthcare ethics. When one considers 
issues such as priority-setting, environmental concerns, sales 
and marketing, and the like, it is not clear that the ethical 
imperatives of the bioscience and healthcare industries 
substantially overlap. This study engages with what might 
be deﬁ  ned as procedural issues, but ignores substantive 
philosophical issues. The latter may have been beyond the 
scope of the paper, but if this were the case, it should have 
been acknowledged. 
Secondly, there is no comment upon the authors’ industry 
links. These are disclosed in their listing of their competing 
interests and include receipt of industry funding, direct links 
with companies subject to study, and funding awarded by 
some of the involved companies after the study. However, 
there is no discussion of the potential for these links to 
interfere with study conduct and interpretation. The authors 
do acknowledge the debate regarding bioethics and links 
with industry, but such acknowledgements cannot realistically 
compensate for the conﬂ  ict of interest faced in the conduct 
of this particular study. Despite the growing literature on 
these links, there is no comprehensive analysis of industry-
associated bioethics research [2,3]. We cannot therefore 
conﬁ  dently claim that there is an observable industry bias in 
such research. There is, however, overwhelming evidence that 
bias favourable toward funders occurs in medical research and 
healthcare prescribing [4–6]. It would therefore seem naive to 
believe that bioethicists are in some way immune from factors 
that demonstrably lead to bias in other disciplines. 
In addition to these omissions, the accompanying 
Perspectives commentary [7] neglects to discuss the 
implications of the conﬂ  icts of interest for the design, 
conduct, conclusions, and interpretation of the study. There 
was an allusion to these conﬂ  icts, but in this context we would 
have expected a review to be far more explicit regarding the 
potentially crucial importance of such conﬂ  icts. 
Ethicists are wooed by industry precisely because their views 
and opinions carry weight. This currency will soon become 
valueless unless researchers, authors, reviewers, and journal 
editors take a strong stand for intellectual honesty and self-
critique in the presence of conﬂ  icts of interest.  
Mark Boyd (E-mail: mark.boyd@fmc.sa.gov.au)
Wendy Rogers
The Flinders University of South Australia
Bedford Park, Australia
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Authors’ Reply
We thank Boyd and Rogers for their comments [1] about 
our article “Lessons on Ethical Decision Making from the 
Bioscience Industry” [2]. 
In response to their ﬁ  rst point, we would like to refer them 
to our book, entitled BioIndustry Ethics, on which our article 
was based [3]. In the introduction of the book, we provide 
a discussion about the intersection of traditional medical 
ethics and business ethics as well as business strategy and 
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explain that it is this intersection that is the focus of our 
study. The decisions made by management in bioscience 
companies (about what drugs to develop, where and how to 
conduct clinical trials, etc.) are not merely procedural but a 
combination of procedural and substantive ethical decision-
making. We would also like to point out that the purpose 
of our article was to highlight the mechanisms being used 
by bioscience companies. It is our belief that by instituting 
processes that encourage ethical discussions (through an 
ethics department, an ethics advisory boards, with ethics 
education and forums for ethics discussion), management 
in bioscience companies will begin to make tough ethical 
decisions openly and consciously. We would like to reiterate 
that our primary audience for this article are decision-makers 
in bioscience companies who, as a ﬁ  rst step, can learn from 
such approaches.
With respect to Boyd and Rogers’ second point, as we write 
in the funding section of the paper, the primary funding 
for this study came from public sources. Moreover, as we 
also emphasise in our book, members of our research team 
with ties to a particular company did not participate in the 
case study of that company. Beyond our disclosing funding 
sources—which is, of course, necessary and appropriate—it 
is not clear what Boyd and Rogers are really asking for. They 
seem to feel our article is incomplete because it is missing an 
exegesis on how this funding might inﬂ  uence our results. In 
fact, we think they are trying to imply that it is inappropriate 
for anyone with industry funding to study ethical practices 
in industry. This is of course not the standard in clinical 
research: the standard is disclosure. But there is something 
more fundamental here. Our study is the very ﬁ  rst, to our 
knowledge, to systematically document practices in bioscience 
companies with respect to ethical challenges. In clinical 
ethics, it took several decades after the advent of ethics 
committees for analogous studies to be conducted. Science 
has a simple solution to Boyd and Rogers’ complaint—it’s 
called replication. Boyd and Rogers themselves, or others, 
should roll up their sleeves and study industry practices 
rather than, like some bioethicists, simply cast aspersions 
about “intellectual honesty and self-critique.” But the logical 
extension of Boyd and Rogers’ critique is that people within 
companies—or with real-world experience of companies’ 
attempts to address ethical challenges—would be ineligible 
to conduct studies aimed at improving companies’ practices 
in response to ethical challenges. This is the type of Alice in 
Wonderland world that is the end result of Boyd and Rogers’ 
world view.  
Jocelyn E. Mackie
Andrew D. Taylor
University of Toronto
Joint Centre for Bioethics
Toronto, Ontario, Canada
David L. Finegold
Keck Graduate Institute of Applied Life Sciences
Claremont, California, United States of America
Abdallah S. Daar
Peter A. Singer (E-mail: peter.singer@utoronto.ca)
University of Toronto
Joint Centre for Bioethics
Toronto, Ontario, Canada
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To Fully Tackle the Gang of Four, 
Needs-Driven R & D Is Essential
Els Torreele, Catherine Royce, Robert Don, Ann-Marie 
Sevcsik, Simon Croft
We congratulate Hotez et al. [1] for a compelling and 
important paper that challenges the global health audience 
to address neglected tropical diseases affecting the poor and 
powerless in resource-poor settings. Full support should be 
given to the call for a global strategy to tackle the neglected 
“gang of four,” which will add the most neglected tropical 
diseases to the well-known big three (HIV/AIDS, malaria, 
and TB). 
For those neglected diseases for which adequate tools exist, 
a strategy of integrated chemotherapy linked to the big three 
could be the best way to reduce disease burden and disease-
related deaths, as is convincingly argued by the authors in the 
case of helminth infections. However, this is a simpliﬁ  cation 
of the situation we face for other neglected tropical diseases 
such as human African trypanosomiasis (HAT), Chagas 
disease, and Buruli ulcer. No adequate tools exist to diagnose 
and treat these fatal or severely debilitating conditions. The 
top priority therefore should be new and innovative research 
and development (R & D) to develop adequate treatments: 
simple and cheap diagnostics and safe, efﬁ  cacious, easy-to-use, 
and affordable medicines.
In the case of HAT, current diagnosis is cumbersome 
and invasive, while the few existing drugs are old, toxic, 
difﬁ  cult to use, and increasingly ineffective [2]. For visceral 
leishmaniasis, another fatal disease when left untreated, 
major treatment complications are invasive diagnostics, long 
durations of treatment (30 d), and drug resistance (up to 
40% in India) [3]. No drugs even exist to treat patients with 
Buruli ulcer or chronic Chagas disease.
Several new initiatives are beginning to address these 
challenges. For instance, the Drugs for Neglected Diseases 
initiative (DNDi) (http:⁄⁄www.dndi.org) was launched 
in 2003 to develop new and ﬁ  eld-adapted treatments for 
neglected diseases like HAT, leishmaniasis, and Chagas 
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disease. The Foundation for Innovative New Diagnostics 
recently initiated a new HAT diagnostics programme, and 
several groups in academia and pharma are increasing their 
R & D efforts in neglected tropical diseases. However, this is 
just a start. These efforts will only come to fruition if sustained 
support can be mobilized.
Needs-driven R & D for new tools is essential, as is 
government support for both R & D and implementation 
of effective interventions when available. In 2005, DNDi 
launched an international R & D appeal (http:⁄⁄www.
researchappeal.org) that urges governments to set global 
public health priorities, to fund R & D for neglected diseases, 
and to provide new rules to stimulate essential health R & 
D. This effort builds on momentum gained over the past 
years to provide an international response to correct the fatal 
imbalance of adequate health tools for neglected diseases. 
We hope all governments will sustain this momentum in May 
2006 at the World Health Assembly, which will consider an 
essential health R & D resolution calling for a global framework 
to support needs-driven research and to set R & D priorities in 
the interest of public health, especially for the most neglected 
diseases [4]. The G8 summit in July provides an opportunity for 
those governments to ﬁ  nancially commit to their 2005 pledge 
to support drug R & D for neglected diseases.
Hotez and colleagues have offered original proposals to 
increase the effectiveness of existing tools in the control of 
certain neglected tropical diseases outside of the big three. 
But to really tackle the gang of four, adequate and ﬁ  eld-
adapted health tools must be available, and governments 
must prioritize needs-driven R & D for those diseases where 
no such tools exist.  
Els Torreele 
Catherine Royce
Robert Don
Ann-Marie Sevcsik (E-mail: amsevcsik@dndi.org)
Simon Croft
Drugs for Neglected Diseases Initiative
Geneva, Switzerland
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Authors’ Reply
We appreciate the comments by our colleagues from the 
Drugs for Neglected Diseases initiative (DNDi) highlighting 
the importance of research and development programs for 
a new generation of control tools (e.g., drugs, diagnostics, 
vaccines, surveillance instruments) to combat the neglected 
tropical diseases [1]. Indeed, we have great admiration for 
the outstanding track record of the DNDi along with its sister 
organizations, including the Institute for One World Health, 
TDR-WHO, and the Seattle Biomedical Research Institute, as 
well as a small but distinguished community of academic and 
government scientists.
In both our paper cited by Torreele et al. [2] and an 
earlier companion paper also published in PLoS Medicine 
[3], we went to some lengths to point out that the ultimate 
elimination of some of the most burdensome endemic 
neglected tropical diseases will likely require more than 
simply innovations in preventative chemotherapy, such 
as our proposed rapid-impact, pro-poor package. Such 
achievements, especially for diseases such as Buruli 
ulcer, hookworm, human African trypanosomiasis, and 
leishmaniasis, will almost certainly also require advances in 
biotechnology leading to the development and distribution 
of new drugs and vaccines. It is also for that reason that 
each of the biomedical scientists who co-authored the PLoS 
Medicine papers has devoted his or her lifetime to research 
on neglected tropical diseases and has contributed to the 
development of new control tools for hookworm, lymphatic 
ﬁ  lariasis, malaria, onchocerciasis, schistosomiasis, and other 
diseases of poverty. In addition, Jeffrey Sachs, the health 
economist on our project, previously led an international call 
to establish a US$1.5 billion Global Health Research Fund, to 
ﬁ  nance basic and applied research on the diseases of poverty 
[4]. In short, we completely agree with the plea by Torreele 
et al. to embrace research and development as an essential 
component for any global neglected tropical disease initiative. 
The major points of our PLoS Medicine articles are these: 
(1) the disease burden of neglected tropical diseases has 
been underestimated and this group of diseases may be as 
important as HIV/AIDS, malaria, and tuberculosis; (2) there 
is a moral imperative to recognize the plight of the world’s 
most impoverished who suffer from neglected tropical 
diseases; and (3) beginning today, we can make a rapid 
impact on the lives of these populations through an effective, 
sustainable, rapid, and highly cost-effective intervention 
package of donated drugs. 
Ultimately, control and elimination of some of our most 
devastating neglected tropical diseases will likely require 
additional biotechnological solutions. Even then, this will 
require careful integration of the new with the old, along the 
lines of the vaccine-linked chemotherapy strategies recently 
proposed by Bergquist et al. [5]. Therefore, we need to do 
our very best to achieve sustainable morbidity reductions 
by using the donated drugs we have in hand today, with the 
understanding that success in this endeavor must not lead 
to complacency. We know all too well how the emergence 
of chloroquine and DDT resistance derailed global malaria 
eradication efforts during the 1960s [6] and that we must 
be ready to simultaneously champion research as well as 
implementation. We also believe that it would be unethical in 
the context of the timeframe of the Millennium Development 
Goals to ignore what we can do for poor people now at such 
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a low cost [7], as we know that research takes time to come 
to fruition in terms of products, policies, ﬁ  nancing, and 
practice. Drugs of proven efﬁ  cacy and quality are available 
now for some of the neglected tropical diseases, and they 
can be delivered despite the resource constraints in African 
health systems. It is gratifying to see a number of countries 
are now prioritizing the control or elimination of neglected 
tropical diseases as a national policy and are establishing 
budget lines to ensure sustainable implementation of the 
tools we have. There have been too many public health 
failures in the past—and so it is essential that we take the real 
opportunity to act on behalf of the world’s poor.  
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Response from Savioli and Colleagues 
from the Department of Neglected 
Tropical Diseases, World Health 
Organization
Lorenzo Savioli, Dirk Engels, Denis Daumerie, Jean 
Jannin, Jorge Alvar, Kingsley Asiedu, Marc Gastellu-
Etchegorry, Pere Simarro, Silvio P. Mariotti
We have read the article by Hotez et al. [1] and the letter by 
Torreele et al. [2].
The priority today is immediate action to expand delivery 
of effective tools and to strengthen the capacity of health and 
innovative delivery systems in the poorest sections of endemic 
countries to tackle the control, elimination, and eradication 
of neglected tropical diseases (NTDs). To this end, it is 
extremely important that all these neglected diseases be 
placed on the global public health agenda. 
Approximately 1 billion people—one person in every 
six—suffer from one or more NTDs, such as Buruli ulcer, 
cholera, cysticercosis, dengue and dengue hemorrhagic 
fever, dracunculiasis (Guinea-worm disease), food-borne 
trematode infections, hydatidosis, leishmaniasis, lymphatic 
ﬁ  lariasis, onchocerciasis, schistosomiasis, soil-transmitted 
helminthiasis, trachoma, Chagas disease, and human African 
trypanosomiasis. Several of these diseases are vector borne. 
Some diseases affect individuals throughout their lives, causing 
a high degree of morbidity and physical disability and, in 
certain cases, gross disﬁ  gurement. Others are acute infections, 
with transient, severe, and sometimes fatal outcomes. Patients 
can face social stigmatization and abuse, which only adds to 
the already heavy disease burden. The common denominator 
of all the NTDs is that these diseases are invariably the diseases 
of the poorest in low-income countries. 
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For the majority of these diseases, inexpensive or donated 
drugs are available for their prevention and control or are 
part of strategies for control and elimination. These, when 
used on a large scale, are able to wipe out the burden caused 
by these ancient scourges of humanity. For leprosy, treatment 
with effective antibiotics, now kindly donated by Novartis, is 
leading to the elimination of this ancient disabling disease. In 
the case of blinding trachoma, the use of the recommended 
SAFE strategy (surgery, antibiotic therapy, facial cleanliness, 
and environmental improvement), including an effective 
antibiotic, donated by Pﬁ  zer through an ad hoc initiative (the 
International Trachoma Initiative), is enhancing the progress 
towards ﬁ  nal elimination. Large-scale, regular treatment 
plays a central role in the control of many NTDs such as 
ﬁ  lariasis, onchocerciasis, schistosomiasis, and soil-transmitted 
nematode infections. For example, regular chemotherapy 
against intestinal worms reduces mortality and morbidity 
in preschool children, improves the nutritional status and 
academic performance of schoolchildren, and improves the 
health and well-being of pregnant women and their infants.
There is a second group of NTDs for which the only clinical 
option currently available is systematic case-ﬁ  nding and 
management at an early stage. These diseases include Buruli 
ulcer, Chagas disease, cholera and other diarrhoeal diseases, 
human African trypanosomiasis, and leishmaniasis. Simple 
diagnostic tools and safe and effective treatment regimens 
urgently need to be developed for these diseases. However, 
even for these infections, systematic and widespread use of 
the present “imperfect” tools at an early stage of disease can 
dramatically reduce mortality, morbidity, and disability. For 
others, vector-control tools are available and present the main 
method for successful transmission control, as in the case of 
Chagas disease.
There are examples of great successes in the ﬁ  ght against 
NTDs in both these groups, and these offer optimism for the 
future. Since 1985, 14.5 million patients have been cured 
of leprosy through multidrug therapy; today, fewer than 1 
million people are newly affected by the disease. Before the 
start of the Guinea-worm Eradication Programme in the early 
1980s, an estimated 3.5 million people were infected with the 
disease in 20 endemic countries. In 2005, only about 10,000 
cases were reported in nine endemic countries, and the 
programme is moving towards eradication by 2009. 
The control of onchocerciasis has freed more than 25 
million hectares of previously onchocerciasis-infested land 
and made it available for resettlement and agricultural 
cultivation, thereby considerably improving rural 
development prospects in Africa and Latin America. During 
the last years, thanks to public–private partnerships with 
sanoﬁ  -aventis, human African trypanosomiasis control 
activities have increased, raising the total number of people 
screened through active case-ﬁ  nding and subsequently 
increasing the access to diagnosis and treatment of affected 
populations. These constant efforts have led to a substantial 
and regular decline in the number of new cases. The number 
of people infected, which were estimated at 300,000 cases in 
1995, has been reduced to 50,000–70,000 in 2005 [3].
In other words, the area of NTDs is not only an area 
lacking drugs and tools that can effectively treat affected 
individuals and communities, but an area of action. As an 
example, praziquantel, a very effective, safe, and relatively 
cheap single-dose drug (approximately 20 Euro cents per 
dose) to treat schistosomiasis, affecting in Africa alone at least 
160 million people, is not accessible to those in need due to 
lack of ﬁ  nancial resources to purchase and deliver it. We also 
have a series of other effective antischistosomal drugs, such 
as oxamniquine and metrifonate, that could again be made 
available in case resistance to praziquantel were to develop. 
Triclabendazole, the only effective drug against fascioliasis, has 
been on the market for veterinary use for over 20 years and is 
still not widely available for human use. Other drugs to tackle 
onchocerciasis and lymphatic ﬁ  lariasis are generously given 
free by the producers, Merck and GlaxoSmithKline, but more 
funds are required to deliver them to the millions in need.
These and many other highly effective drugs developed 
in the late 1970s are now out of patent but still not available 
to poor communities. We are well aware that “market 
mechanisms” will never solve the problem of access to 
effective drugs in the poorest communities of the low-income 
countries. Therefore, drug donations and funds for drug 
delivery are needed to tackle a problem that is intimately 
linked to underdevelopment and marginalization. 
Global health development policies must also be more 
balanced in allocating resources to research and control. For 
instance, the recent resolution of the European Parliament 
[4] is indeed a sign of great progress. However, this 
document tackles disproportionately the lack of tools and the 
need for research in drug development. We believe that—
above all—priority should be given to generating resources 
to deliver the drugs already available to those in need while 
monitoring their use and efﬁ  cacy. 
WHO is expanding activities in this area. WHO has very 
recently developed guidelines towards effective integrated 
implementation of large-scale preventive chemotherapy 
strategies in consultation with Member States, academic 
organizations, and other partners. We believe these 
guidelines will be essential for Member States and interested 
non-governmental organizations to tackle the problem of 
NTDs in their countries on a large scale. 
We agree that this need for immediate action in the 
medium- and long-term must be backed up by research and 
development of new drugs, vaccines (like those presently 
developed against hookworms), diagnostics, and other 
tools. We believe that focusing mainly on research and 
development at this stage is overshadowing the importance 
of reducing mortality, morbidity, and disability now with the 
existing technology.  
Lorenzo Savioli (E-mail: saviolil@who.int) 
Dirk Engels
Denis Daumerie
Jean Jannin
Jorge Alvar
Kingsley Asiedu
Marc Gastellu-Etchegorry
Pere Simarro
World Health Organization 
Department of Control of Neglected Tropical Diseases
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June 2006  |  Volume 3  |  Issue 6  |  e283PLoS Medicine  |  www.plosmedicine.org 0938
Chronic Disease Prevention and Management
Geneva, Switzerland
References
1.  Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Sachs SE, et al. (2006) 
Incorporating a rapid impact package for neglected tropical diseases with 
programmes for HIV/AIDS, tuberculosis, and malaria. PLoS Med 3: e102. 
DOI: 10.1371/journal.pmed.0030102
2.  Torreele E, Royce C, Don R, Sevcsik AM, Croft S (2006) To fully tackle 
the gang of four, needs-driven R & D is essential. PLoS Med 3: e282. DOI: 
10.1371/journal.pmed.0030282
3.  World Health Organization (2006) Human African trypanosomiasis 
(sleeping sickness): epidemiological update. Weekly Epidemiol Rec 81: 
71-80. Available: http://www.who.int/wer/2006/wer8108/en/index.html. 
Accessed 13 May 2006.
4.  European Parliament (2005) Resolution on major and neglected 
diseases in developing countries. 2005/2047(INI). Available: 
http:⁄⁄www.europarl.eu.int/omk/sipade3?PUBREF=-⁄⁄EP⁄⁄
TEXT+TA+P6-TA-2005-0341+0+DOC+XML+V0//
EN&L=EN&LEVEL=0&NAV=S&LSTDOC=Y&LSTDOC=N. 
Accessed 13 May 2006. 
Citation: Savioli L, Engels D, Daumerie D, Jannin J, Alvar J, et al. (2006) Response 
from Savioli and colleagues from the Department of Neglected Tropical 
Diseases, World Health Organization. PLoS Med 3(6): e283. DOI: 10.1371/journal.
pmed.0030283
Copyright: © 2006 Savioli et al. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author 
and source are credited.
Funding: The authors received no speciﬁ  c funding for this article. 
Competing Interests: The authors have declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0030283
Merck’s Actions Surrounding Vioxx
Michael Heinley
Merck has always been committed to the highest standards of 
scientiﬁ  c integrity, patient safety, and ethics. In his part of the 
PLoS Medicine Debate entitled “What Are the Public Health 
Effects of Direct-to-Consumer Drug Advertising,” Richard 
Kravitz incorrectly characterizes Merck’s actions surrounding 
Vioxx [1]. 
Any suggestion that Merck acted improperly in the 
development and marketing of Vioxx is simply false. Vioxx 
was a widely used medicine because it served as an effective 
therapy for patients for whom—in many instances—no other 
alternative medicine worked. Merck’s marketing efforts for 
Vioxx provided balanced and accurate information about 
both the product’s considerable beneﬁ  ts for patients living 
with chronic pain as well as its potential risks. 
Merck remains committed to producing innovative, safe, 
and therapeutic medicines for patients and to upholding 
the highest standards of scientiﬁ  c integrity. Our reputation 
in the industry, with patients and our community, is that of 
a company that puts patients ﬁ  rst. We intend to keep it that 
way.
To learn more about Merck’s actions, please visit the Vioxx 
Information Center on our Web site at http:⁄⁄www.merck.
com/newsroom.
Michael Heinley (E-mail: michael_heinley@merck.com)
Merck & Company
Whitehouse Station, New Jersey, United States of America
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Author’s Reply
In my section of the PLoS Medicine Debate entitled “What 
Are the Public Health Effects of Direct-to-Consumer Drug 
Advertising?” [1], I noted that a two-year moratorium on 
direct-to-consumer (DTC) advertising of new drugs could 
“avoid another Vioxx tragedy, in which drug marketing got 
well ahead of the science.” Contrary to Michael Heinley’s 
complaint [2], I did not suggest that Merck acted improperly. 
That is a matter for the courts to decide. My only point was 
that obtaining more information on the risk:beneﬁ  t ratio of 
Vioxx prior to mass marketing would have resulted in more 
informed prescribing. 
From the time of its approval on May 21, 1999, until its 
voluntary withdrawal on September 30, 2004, Vioxx was 
prescribed to more than 80 million patients [3]. During much 
of that time, Merck conducted a vigorous and highly successful 
DTC marketing campaign. Whatever one believes about early 
signals of excess cardiovascular risk, by 2004 the results of the 
APPROVe trial had convinced everyone, including Merck, that 
Vioxx represented a potential threat to public health [4,5]. 
In the meantime, hundreds of thousands of patients sought 
and received Vioxx prescriptions as a result of watching DTC 
advertisements on television, and up to 16 per 1,000 may have 
suffered untimely myocardial infarctions or strokes as a result 
[3]. If there had been a DTC advertising moratorium in place 
beginning in 1999, the science of adverse-event monitoring 
might have had a ﬁ  ghting chance to catch up.  
Richard L. Kravitz (E-mail: rlkravitz@ucdavis.edu)
University of California Davis
Davis, California, United States of America
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